New England Journal of Medicine · 1977 · 436 citations · 32 references
Life SciencesImmunologyNeurologyAutoimmunityImmunotherapyNeuromuscular DisordersAutoantibodiesAutoimmune Disease DiagnosticsAutoimmune DiseasesMyasthenia GravisNeuromuscular JunctionNeuromuscular Junction DisordersAnti-muscle-specific Kinase AntibodiesConfirmatory Diagnostic TestingMuscle-specific Kinase AntibodiesMyasthenia Gravis TestingNeuromuscular Junction AntibodiesNeuromuscular Junction TransmissionRespiratory Muscle InvolvementRespiratory Musculature
To study the role of humoral factors in the pathogenesis of myasthenia gravis, we employed passive transfer of human serum fractions to mice. Immunoglobulins from 16 patients with myasthenia gravis were injected into mice daily for one to 14 days. Typical myasthenic features of reduction in amplitude of miniature end-plate potentials (mean change more than 50 per cent, P less than 0.005) or reduction in acetylcholine receptors at neuromuscular junctions (mean change more than 50 per cent, P less than 0.005) (or both) were produced by immunoglobulin from 15 of the 16 patients. Some mice showed weakness or decremental responses to repetitive nerve stimulation as well. The active fraction was identified as IgG by three different purification methods. Its effect was enhanced by the third component (C3) of the complement system, but the fifth component (C5) had no effect. These data suggest that the pathogenesis of myasthenia gravis often involves and antibody-mediated autoimmune attack on the acetylcholine receptors of the neuromuscular junction.
32
Autoimmune Response to Acetylcholine Receptor
Jim Patrick, Jon Lindstrom · Science · 1973 · 1K citations
Medicine, Immunology, Neurology +13
Myasthenia Gravis: A New Hypothesis
John A. Simpson · Scottish Medical Journal · 1960 · 589 citations